Newfeed

Design of the multi-center study is based on Phase 2a clinical data, which showed a decrease in the occurrence of severe bronchopulmonary dysplasia (BPD), a condition for which there are no approved therapies.OHB-607 has the potential to be the first innovative respiratory therapeutic advance for e

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: